Source comparison
Thymosin Alpha-1 for Alopecia Areata: Clinical vs Procedural Comparison
Thymosin alpha-1 (1.6mg 2x/week SC) Treg upregulation, CD8+ T-cell suppression 40–60% regrowth >50% baseline 12–16 weeks Injection site erythema (18%), transient flu-like symptoms (12%) Works when immune attack is Th1-driven and follicles remain intact. Ineffe
This comparison does not assign a generated winner or score.
- Thymosin alpha-1 (1.6mg 2x/week SC)
- Treg upregulation, CD8+ T-cell suppression
- 40–60% regrowth >50% baseline
- 12–16 weeks
- Injection site erythema (18%), transient flu-like symptoms (12%)
- Works when immune attack is Th1-driven and follicles remain intact. Ineffective in alopecia totalis
- Intralesional triamcinolone (10mg/mL monthly)
- Local corticosteroid suppression of follicular inflammation
- 50–70% regrowth in treated patches
- 6–8 weeks
- Skin atrophy (25%), hypopigmentation (15%), rebound flare on discontinuation
- Faster onset but high rebound risk and cosmetic side effects
- JAK inhibitors (tofacitinib 5mg PO BID)
- Inhibition of JAK1/JAK3 pathways blocking IFN-γ signaling
- 60–80% regrowth in moderate-severe AA
- 16–24 weeks
- Infection risk, lipid abnormalities, GI upset (30%)
- Most effective for extensive disease but requires ongoing systemic immunosuppression
- Topical minoxidil 5% BID
- Vasodilation, potassium channel opening in follicular dermal papilla
- 20–30% regrowth as monotherapy
- Scalp irritation (12%), hypertrichosis on face if misapplied
- Adjunct only. Does not address autoimmune mechanism